GlassScriptPhysician profile
Cheryl A Herrmann
NPI 1578590337
$361.80
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $45.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $83.05 | 2019-2020 | |
| Glaxosmithkline, LLC. | $47.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $36.69 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.57 | 2019 | |
| Pfizer INC. | $24.82 | 2019 | |
| Astellas Pharma US INC | $23.27 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.06 | 2019 | |
| Amgen INC. | $19.89 | 2020 | |
| Amarin Pharma, INC. | $12.84 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.34 | 2019 | |
| Allergan, INC. | $11.73 | 2019 | |
| Lilly USA, LLC | $11.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Herrmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.